Income statement
SGD
Annual
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 168K | 2M | 651K |
| Gross Profit | 37K | 898K | 115K |
| Operating Income | -5M | -3M | -2M |
| EBITDA | -5M | -2M | -1M |
| Net Income | -5M | -2M | -2M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.322
-5.85% today
Window Change
-34.95%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phaos Technology Holdings (Caym (POAS) is a Healthcare stock with a market cap of $40.00M and listed on AMEX. The stock last traded around $0.32 and down 34.9% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of -91.1%, EPS growth of -116.7%, a dividend yield of 0.0%. What stands out right now is revenue -91.1%, EPS -116.7%, free cash flow -125.0% with operating margin -3148.3% and ROIC 311.1%. Valuation already assumes a fairly strong business story at price/sales 241.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POAS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POAS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POAS Max Drawdown
-45.86%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for POAS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$650.8K
-65.4% YoY
FY Net Income
-$1.7M
+29.3% YoY
Free Cash Flow
-$2.0M
-15.9% YoY
Revenue Growth
-91.1%
EPS Growth
-116.7%
Gross Margin
22.1%
Net Margin
-3063.1%
Income statement
SGD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 168K | 2M | 651K |
| Gross Profit | 37K | 898K | 115K |
| Operating Income | -5M | -3M | -2M |
| EBITDA | -5M | -2M | -1M |
| Net Income | -5M | -2M | -2M |
| EPS (Diluted) | — | — | — |
Balance sheet
SGD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & Equivalents | 130K | 2M | 54K |
| Total Assets | 2M | 5M | 1M |
| Total Liabilities | 4M | 2M | 4M |
| Shareholder Equity | -2M | 3M | -3M |
| Total Debt | 266K | 793K | 885K |
| Net Debt | 136K | -2M | 831K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-11.1% YoY
Capital Expenditures
218K
-79.4% YoY
Free Cash Flow
2M
-15.9% YoY
Key ratios
Gross Margin
22.1%
Operating Margin
-3148.3%
Net Margin
-3063.1%
ROE
-1073.1%
Debt / Equity
-0.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.